Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 168

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

Open access
Pal, Sumanta K., Tran, Ben, Haanen, John B.A.G., Hurwitz, Michael E., Sacher, Adrian, Tannir, Nizar M., Budde, Lihua E., Harrison, Simon J., Klobuch, Sebastian, Patel, Sagar S., Meza, Luis, Dequeant, Mary-Lee, Ma, Anna, He, Qiuling Ally, Williams, Leah M., Keegan, Alissa, Gurary, Ellen B., Dar, Henia, Karnik, Sushant, Guo, Changan, Heath, Heidi, Yuen, Rachel R., Morrow, Phuong K., Agarwal, Neeraj, Srour, Samer A. · 2024 · Cancer Discovery

Abstract

Therapeutic approaches for clear cell renal cell carcinoma (ccRCC) remain limited; however, chimeric antigen receptor (CAR) T-cell therapies may offer novel treatment options. CTX130, an allogeneic CD70-targeting CAR T-cell product, was developed for the treatment of advanced or refractory ccRCC. We report that CTX130 showed favorable preclinical proliferation and cytotoxicity profiles and completely regressed RCC xenograft tumors. We also report results from 16 patients with relapsed/refractory ccRCC who received CTX130 in a phase I, multicenter, first-in-human clinical trial. No patients encountered dose-limiting toxicity, and disease control was achieved in 81.3% of patients. One patient remains in a durable complete response at 3 years. Finally, we report on a next-generation CAR T construct, CTX131, in which synergistic potency edits to CTX130 confer improved expansion and efficacy in preclinical studies. These data represent a proof of concept for the treatment of ccRCC and other CD70+ malignancies with CD70− targeted allogeneic CAR T cells. Significance: Although the role of CAR T cells is well established in hematologic malignancies, the clinical experience in solid tumors has been disappointing. This clinical trial demonstrates the first complete response in a patient with RCC, reinforcing the potential benefit of CAR T cells in the treatment of solid tumors. See corresponding author Sumanta K. Pal discuss this research article, published simultaneously at the AACR Annual Meeting 2024: https://vimeo.com/932606570/887520f9cb

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-24-0102

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 168

Metadata

Authors
Pal, S. K., Tran, B., Haanen, J. B. A. G., Hurwitz, M. E., Sacher, A., Tannir, N. M., Budde, L. E., Harrison, S. J., Klobuch, S., Patel, S. S., Meza, L., Dequeant, M.-L., Ma, A., He, Q. A., Williams, L. M., Keegan, A., Gurary, E. B., Dar, H., Karnik, S., Guo, C., Heath, H., Yuen, R. R., Morrow, P. K., Agarwal, N., & Srour, S. A.
Venue
Cancer Discovery
Published
2024-04-04
Volume
14
Issue
7
Pages
1176-1189
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W4394060769
Cited by
168
References
8
FWCI
25.78
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. https://app.cochat.ai/papers/10.1158/2159-8290.cd-24-0102
The paper
Pal, S. K., Tran, B., Haanen, J. B. A. G., Hurwitz, M. E., Sacher, A., Tannir, N. M., Budde, L. E., Harrison, S. J., Klobuch, S., Patel, S. S., Meza, L., Dequeant, M.-L., Ma, A., He, Q. A., Williams, L. M., Keegan, A., Gurary, E. B., Dar, H., Karnik, S., . . . Srour, S. A. (2024). CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-24-0102

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.